MK-677 and Rosuvastatin Interaction

Avoid
Mechanism-based 64% confidence

MK-677 and Rosuvastatin have a potentially harmful interaction with 64% confidence. Both MK-677 and Rosuvastatin carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. These compounds primarily affect different organ systems.

Compound Profiles

MK-677

Ghrelin Receptor Agonist | Oral Growth Hormone Secretagogue

Selectively binds GHS-R1a receptors in hypothalamus and pituitary, triggering pulsatile growth hormone release while maintaining natural circadian patterns..

Half-life: ~24 hours Typical dose: Start 12.5mg daily, increase to 25mg based on tolerance growth hormone, weight loss, sleep
ghrelin receptor blood pressure raisingcarcinogenic riskhepatotoxicinsulin disrupting
View full profile

Rosuvastatin

HMG-CoA Reductase Inhibitor | Statin for Lipid Management

Rosuvastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway responsible for hepatic cholesterol synthesis. By blocking this enzyme, rosuvastatin reduces intracellular cholesterol in hepatocytes, which triggers upregulation of LDL receptor expression on the liver cell surface.

Half-life: ~19 hours Typical dose: 5-20 mg/day cardiovascular
hepatotoxiclipid disruptingteratogenic
View full profile

Combined Organ Load

Brain
low
GI Tract
low
Pituitary
low
Heart
low

Shared Safety Flags

2x 2 hepatotoxic compounds (MK-677, Rosuvastatin). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.
2x 2 compounds share the teratogenic safety flag (MK-677, Rosuvastatin). Monitor accordingly.

Frequently Asked Questions

Can I take MK-677 with Rosuvastatin?

Combining MK-677 with Rosuvastatin is not recommended. Both MK-677 and Rosuvastatin carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is MK-677 and Rosuvastatin safe together?

This combination carries significant risk. Both MK-677 and Rosuvastatin carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between MK-677 and Rosuvastatin?

Both MK-677 and Rosuvastatin carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.

How should I time MK-677 and Rosuvastatin?

MK-677 has a half-life of ~24 hours and Rosuvastatin has a half-life of ~19 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: MK-677 vs Rosuvastatin

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.